POS0657 SURVIVAL OF BARICITINIB VS ANTI-TNF AS THE FIRST BIOLOGICAL DRUG IN PATIENTS WITH RHEUMATOID ARTHRITIS, IN CLINICAL PRACTICE: RESULTS OF A LOCAL REGISTRY

Objectives To evaluate survival in the first 4 years of treatment with Baricitinib (BARI) vs anti-TNF (TNFi), as biological drug (BIO-1), patients rheumatoid arthritis (RA). Methods Retrospective study RA, treated BIO-1, BARI or TNFi, from September-2017 to December-2021. General data (current age, at diagnosis RA and start BIO-1) were collected; RA: evolution time, RF, ACPA; type BIO-1: dose received, time treatment, reason for withdrawal. Univariate analysis was performed using Kaplan-Meyer curves Long Rank test differentiate by groups. For multivariate study, Cox regression proportional hazards. Results The includes 96 who have started > 1 month (n: 63/66% patients) TNFi (33/34% patients): women: 82 (96%), current mean age (SD): 62 (1) years, diagnosis: 51 59 years. 36 (37%) are ≥65 old, AR is 7.6 1.34 (2.2) BIO-1 withdrawn 34 (40%) patients: Inefficacy: 17 (18%) patients, Complications: 14 (15%) [Cardiovascular/thrombosis: 2 (2%), rash: infection-neoplasia-immunogenicity: (1%) patient each], loss follow-up: 5 (5%) others: (2%). When comparing vs. TNFI group, no differences detected between general data, percentage >65 reasons withdrawal (Table 1). However, group significantly superior throughout period (p=0.04; HR: 0.47, 95% CI: 0.24-0.91, p=0.026) (Figure 1A). Table 1. Characteristics receive (TNFi). AllN: BARIN: 63 (66%) TNFiN: 33 (34%) P Female, n (%) (85%) 56 (89) 26 (79) 0.2 Current (SD) (4.2) (6) (11) 0.057 Age (4.9) 52.5 (7.8) 48.6 (15.5) 0.17 (2.1) 60 55.9 (9.9) 0.23 ≥ 65 (37) 27 (43) 9 (27) 0.39 RF positive, 77 (80) 54 (86) 23 (70) 0.1 ACPA 74 (77) 50 24 (73) 0.56 Average (DE) 1.85 (0.5) 1.32 (2.4) 0.21 mg, - (36) Withdrawal (%): 38 (40) 20 (32) 18 (55) 0.15 Complication (15) 7 (13) (21) Loss efficacy (18) 8 follow up (5) (8) Other (2) Figure Survival probability BIO-1. A . Between Baricitinib. B mg mg. In <65 greatest maintained (p=0.05), being significant months (p=0.02). significance not reached overall (p=0.5) (p=0.06). 23/36%) 40/64%) groups, older (73 [SD: 2] 3] years; p<0.0001) (72 1.4] 2.8] p<0.0001). higher (p=0.003;) 1B): 0.14, CI; 0.04-0.56, p=0.005, HR mg: 0.44 (95% 0.20-0.96, p=0.038). Conclusion during especially treatment. 2. There cause that causes 3. use predominates than greater Acknowledgements supported a research grant Marina Baixa Association Research Rheumatology (AIRE-MB). Disclosure Interests None declared